PT003

DRUG3 trials

Sponsors

Pearl Therapeutics, Inc.

Conditions

Chronic Obstructive Pulmonary DiseaseHealthy Volunteers

Phase 1

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

CompletedNCT00893971

Pearl Therapeutics, Inc.Healthy Volunteers

Start: 2009-05-31End: 2009-07-31Updated: 2017-04-26

Phase 2

PT003 MDI Dose Confirmation Study

CompletedNCT01349816

Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disease

Start: 2011-06-30End: 2011-11-30Updated: 2017-04-27

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

CompletedNCT01587079

Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disease

Start: 2012-04-30End: 2012-10-31Updated: 2016-06-30

Related Papers

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.

2018-06-195 citations

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.

2018-04-136 citations

A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.

2016-09-1718 citations

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.

2016-09-0212 citations